We then explored whether SGK1 and pNDRG1 expression correlate with clinical outcome to PI3Kα inhibition by analyzing PIK3CA-mutant breast cancer samples from 18 patients treated with BYL719 in combination with an aromatase inhibitor (NCT01870505). Here, CYP19A1 is linked to breast carcinoma.